A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374 on ClinicalTrials.gov · last registry update 2026-09-01
An unusually large phase 3: 1,100 participants, more than double the 424 typical for the stage. Due to report September 2028, alongside 21 other tracked readouts that quarter. Primary outcome, as filed: Percent change in body weight from Baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. aleniglipron is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- RECRUITING
- Phase
- P3
- Drug
- aleniglipron
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Sponsor type
- Industry
- Enrollment
- 1,100
- Started
- 2026-07-17
- Primary completion
- 2028-09 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-21 | First seen in registry | Registered as RECRUITING, P3 |
Primary outcome
Percent change in body weight from Baseline
Conditions studied
Obesity · Overweight · Chronic Weight Management · Type2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the aleniglipron page for this molecule’s full trial and approval history.